Podcasts about cebm

In our final episode of Season 3, we take an in-depth look at Clearstream's newly added central bank money (CeBM) settlement for triparty repo. Integrated with the EU's TARGET2 real-time gross settlement platform, CeBM opens up uncleared triparty repos to a wider market of more diverse financial and non-financial counterparties. CeBM is designed to facilitate entities such as debt management offices and state treasuries that want to engage in the reduced risk of central bank money settlement, with less friction and back-office complexity for lifecycle events. As repo volumes increase and inflation, volatility and interest rates continue to be unpredictable, CeBM adds another liquidity management tool into the money markets in an industry first for Clearstream. Join James Cherry, Head of Business Development (and long-time contributor) and Christian Rossler as they break down the key issues and look ahead to the big macroeconomic issues that will shape the next year of global funding and financing. 

THE CENTRE OF EXCELLENCE FOR BEHAVIOUR MANAGEMENT (CEBM) ​As a support to the 10 English School Boards of Quebec, the CEBM aims to enable boards and their staff to find developmentally friendly and trauma informed interventions that are effective in helping students who are struggling with behavioural challenges in the school setting.​ Visit https://www.cebm.ca  

The world for the past few months has been speaking a lot on COVID vaccines and how it is our way out of this pandemic. But it will be a long time before the entire world is vaccinated. So what do we do to prevent severe symptoms or hospitalisation till then? A new anti-viral pill for COVID-19 treatment from pharma giants Merck and Pfizer Inc, aims to reduce the risk of hospitalisation and even death. These new drugs – Merck's Molnupiravir and Pfizer's Paxlovid – are currently in their clinical trials but have shown promising results, especially the latter, which claims to reduce the risk of hospitalisation by 89 percent. And countries have already started recognising the significance of these pills, with the United Kingdom being the first country to approve Molnupiravir and purchased nearly half a million courses. So what are these new drugs exactly? How do they work and more importantly, are they safe? Host and Producer: Himmat Shaligram Guest: Vaishali Sood, The Quint's Health Editor and Dr Rakesh Mishra, the former Director of Council of Scientific and Industrial Research and an Advisor to CEBM. Editor: Shelly Walia Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur

COVID-19 is here to stay for longer than we could have imagined, while vaccine stocks in the world are nowhere near enough to keep populations across the globe safe from future surges. Keeping in mind the shortage of vaccine supply, countries have started to consider mixing and matching of different COVID vaccines and the data so far seems promising, according to experts.A recent study led by researchers at Oxford University found that mixing the Oxford-AstraZeneca and Pfizer-BioNTech vaccines is safe, although it could cause more severe, albeit temporary, side effects.Similar studies were conducted in Spain, which also showed encouraging results. Countries like Canada, the UK, Bahrain and the UAE have also started allowing the mixing and matching of vaccines to address the shortage of supply.However, researchers and experts in India are still on the fence about the issue, citing a lack of clinical data for the vaccines approved in India – which are Oxford Astrazeneca also known as Covishield, Covaxin, and Sputnik V. In today's episode, we will take a closer look at what Indian experts have to say on mixing and matching of COVID vaccines, whether it is safe, and whether given the severe shortage of vaccines that India is facing, should we consider it?Host and Producer: Himmat Shaligram Guest: Professor Gagandeep Kang, a renowned virologist with CMC Vellore, and Dr Rakesh Mishra, the former Director of Council of Scientific and Industrial Research and an Advisor to CEBM. Editor: Shelly Walia Music: Big Bang FuzzListen to The Big Story podcast on:Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur

India is yet to recover from the severe second wave of COVID-19. We're still facing shortages of oxygen and vaccine, amid growing concern over black fungus cases. But there's already an alarm for an impending third wave of the virus. COVID has been with us for over a year now and almost every state in India has witnessed its own wave — while Maharashtra is experiencing its third wave this year and Delhi is in its fourth. But as the virus continues to mutate, many experts have opined that a third wave will arrive soon. However, its timeline and strength are still speculative.Even the Centre's Principal Scientific Advisor Dr K Vijay Raghavan stated on 5 May that a third wave is inevitable but later modified his remarks, saying that it can be avoided if India takes strong measures. Which prompts the question — how can we prepare to tackle the next wave of the virus? What lessons have we learnt from the second wave and what steps can the Centre take to weaken the impact of the next surge? Host and Producer: Himmat Shaligram Guest: Dr Rakesh Mishra, the Former Director of Council of Scientific and Industrial Research and an Advisor to CEBM, and Dr Giridhar R Babu a Professor of Life-course Epidemiology at the Public Health Foundation of India. Editor: Shelly WaliaReferences: Lack of Tests & Ventilators: How Rural India Is Facing COVID Surge Music: Big Bang FuzzListen to The Big Story podcast on:Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur

Purpose:  Learn the importance of treatment studies (RCTs) in EBM  Understand and interpret methods and results of treatment based studies  Become familiar with critically appraising treatment based studies   Hosts:  Dylan Collins  Levi Johnston Dakoda Herman Jayneel Limbachia Jake Domm   Paper:  Warren, Jaimee, et al. "Antacid Monotherapy Is More Effective in Relieving Epigastric Pain Than in Combination With Lidocaine: A Randomized Double‐blind Clinical Trial." Academic Emergency Medicine 27.9 (2020): 905-909. https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.14069    EBM Checklist for therapy studies (University of Oxford: https://www.cebm.net/wp-content/uploads/2018/11/RCT.pdf    Episode takeaway  RCTs are considered gold standard in terms of evidence since the randomization process controls for both known and unknown confounding variables  Understanding how to quickly and efficiently appraise studies by assessing its methods is an important skill that can help you assess its utility to your practice and whether the authors adequately answered the question Use a validated critical appraisal tool. We used the CEBM tool, but there are others. The GATE from by Rod Jackson is another great method to learn. Know that sometimes people use publishing guidelines as critical appraisal tools, like the CONSORT for RCTs, but these are just work arounds.  Be skeptical and curious. If there is a published protocol, check it. Look at who funded the study. Read the COI and method to mitigate bias.

Purpose:  Learn the importance of treatment studies (RCTs) in EBM  Understand and interpret methods and results of treatment based studies  Become familiar with critically appraising treatment based studies   Hosts:  Dylan Collins  Levi Johnston Dakoda Herman Jayneel Limbachia Jake Domm   Paper:  Warren, Jaimee, et al. "Antacid Monotherapy Is More Effective in Relieving Epigastric Pain Than in Combination With Lidocaine: A Randomized Double‐blind Clinical Trial." Academic Emergency Medicine 27.9 (2020): 905-909. https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.14069    EBM Checklist for therapy studies (University of Oxford: https://www.cebm.net/wp-content/uploads/2018/11/RCT.pdf    Episode takeaway  RCTs are considered gold standard in terms of evidence since the randomization process controls for both known and unknown confounding variables  Understanding how to quickly and efficiently appraise studies by assessing its methods is an important skill that can help you assess its utility to your practice and whether the authors adequately answered the question Use a validated critical appraisal tool. We used the CEBM tool, but there are others. The GATE from by Rod Jackson is another great method to learn. Know that sometimes people use publishing guidelines as critical appraisal tools, like the CONSORT for RCTs, but these are just work arounds.  Be skeptical and curious. If there is a published protocol, check it. Look at who funded the study. Read the COI and method to mitigate bias.

Purpose: 1. Learn the importance of treatment studies (RCTs) in EBM 2. Understand and interpret methods and results of treatment based studies 3. Become familiar with critically appraising treatment based studies Hosts: Dylan Collins Levi Johnston Dakoda Herman Jayneel Limbachia Jake Domm Paper: Warren, Jaimee, et al. "Antacid Monotherapy Is More Effective in Relieving Epigastric Pain Than in Combination With Lidocaine: A Randomized Double‐blind Clinical Trial." Academic Emergency Medicine 27.9 (2020): 905-909. https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.14069EBM Checklist for therapy studies (University of Oxford: https://www.cebm.net/wp-content/uploads/2018/11/RCT.pdf Episode takeaway 1. RCTs are considered gold standard in terms of evidence since the randomization process controls for both known and unknown confounding variables 2. Understanding how to quickly and efficiently appraise studies by assessing its methods is an important skill that can help you assess its utility to your practice and whether the authors adequately answered the question 3. Use a validated critical appraisal tool. We used the CEBM tool, but there are others. The GATE from by Rod Jackson is another great method to learn. Know that sometimes people use publishing guidelines as critical appraisal tools, like the CONSORT for RCTs, but these are just work arounds. 4. Be skeptical and curious. If there is a published protocol, check it. Look at who funded the study. Read the COI and method to mitigate bias.

Purpose: 1. Learn the importance of treatment studies (RCTs) in EBM 2. Understand and interpret methods and results of treatment based studies 3. Become familiar with critically appraising treatment based studies Hosts: Dylan Collins Levi Johnston Dakoda Herman Jayneel Limbachia Jake Domm Paper: Warren, Jaimee, et al. "Antacid Monotherapy Is More Effective in Relieving Epigastric Pain Than in Combination With Lidocaine: A Randomized Double‐blind Clinical Trial." Academic Emergency Medicine 27.9 (2020): 905-909. https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.14069EBM Checklist for therapy studies (University of Oxford: https://www.cebm.net/wp-content/uploads/2018/11/RCT.pdf Episode takeaway 1. RCTs are considered gold standard in terms of evidence since the randomization process controls for both known and unknown confounding variables 2. Understanding how to quickly and efficiently appraise studies by assessing its methods is an important skill that can help you assess its utility to your practice and whether the authors adequately answered the question 3. Use a validated critical appraisal tool. We used the CEBM tool, but there are others. The GATE from by Rod Jackson is another great method to learn. Know that sometimes people use publishing guidelines as critical appraisal tools, like the CONSORT for RCTs, but these are just work arounds. 4. Be skeptical and curious. If there is a published protocol, check it. Look at who funded the study. Read the COI and method to mitigate bias.

Host: Elizabeth Esty, MD. At this point, with so many of the studies we’ve digested exploring correlations, associations, observational studies and anecdotal reports and speculation, we could subtitle the show: what we don’t know about COVID. And so, today, we’ll look at what we don’t know about Vitamin D and COVID. There have been a number of studies and a fair amount of media coverage in recent weeks that look at a possible link between low Vitamin D levels and severity of COVID.  Vitamin D plays a role in both adaptive and innate immunity, which we discussed at some length in our episode on the BCG vaccine and COVID. Macrophages starved for Vitamin D can’t produce peroxide to kill microbes, and some of the toll-like receptors crucial to innate immunity that recognize pathogen molecules don't work right without Vitamin D. Finally, Vitamin D modulates the immune response, preventing release of too many cytokines. The potential for Vitamin D to play a role in preventing severe COVID-19 seems plausible, but what does the science say? Research By: Elizabeth Esty and Nathan Novotny. Sound Editing By: Nathan Novotny. References: [1] Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. 3, Overview of Vitamin D. Available from: https://www.ncbi.nlm.nih.gov/books/NBK56061/ [2] Helming L, Böse J, Ehrchen J, et al. 1α,25-dihydroxyvitamin D3 is a potent suppressor of interferon γ–mediated macrophage activation. Blood. 2005;106(13):4351-4358. doi:10.1182/blood-2005-03-1029   [3] Parva NR, Tadepalli S, Singh P, et al. Prevalence of Vitamin D Deficiency and Associated Risk Factors in the US Population (2011-2012). Cureus. 10(6). doi:10.7759/cureus.2741 [4] Sizar O, Khare S, Goyal A, Bansal P, Givler A. Vitamin D Deficiency. In: StatPearls. StatPearls Publishing; 2020. Accessed May 21, 2020. http://www.ncbi.nlm.nih.gov/books/NBK532266/ [5] Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. Published online May 6, 2020. doi:10.1007/s40520-020-01570-8 [6] Vitamin D and Inflammation – Potential Implications for Severity of Covid-19 – Irish Medical Journal. Accessed May 21, 2020. http://imj.ie/vitamin-d-and-inflammation-potential-implications-for-severity-of-covid-19/ [7] Raharusun P, Priambada S, Budiarti C, Agung E, Budi C. Patterns of COVID-19 Mortality and Vitamin D: An Indonesian Study. Social Science Research Network; 2020. doi:10.2139/ssrn.3585561 [8] The Center for Evidence Based Medicine. Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19. CEBM. Accessed May 21, 2020. https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/ [9] Hastie CE, Mackay DF, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):561-565. doi:10.1016/j.dsx.2020.04.050

This edition of talk evidence was recorded before the big increase in covid-19 infections in the UK, and then delayed by some self isolation. We'll be back with more evidence on the pandemic very soon. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence). in this episode (1.01) Helen talks about variation in prescription of opioids - do 1% of clinician really prescribe the vast majority of the drug? (8.45) Carl tells us that its time papers (in this case a lung screening one) really present absolute numbers. (17.30) Carl explains how a spoonfull (less) of salt helps the blood pressure go down (21.25) Helen puts test results under a microscope, and finds out that they may vary. (33.20) What do conflicts of interest in tanning papers mean for wider science? (48.05) Carl has a "super-rant" about smartphone apps for skin cancer - and a sensitivity of 0. Reading list: Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study https://www.bmj.com/content/368/bmj.l6968 Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1911793 Effect of dose and duration of reduction in dietary sodium on blood pressure levels https://www.bmj.com/content/368/bmj.m315 Your results may vary: the imprecision of medical measurements https://www.bmj.com/content/368/bmj.m149 Association between financial links to indoor tanning industry and conclusions of published studies on indoor tanning: systematic review https://www.bmj.com/content/368/bmj.m7 Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies https://www.bmj.com/content/368/bmj.m127

This edition of talk evidence was recorded before the big increase in covid-19 infections in the UK, and then delayed by some self isolation. We'll be back with more evidence on the pandemic very soon. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence). in this episode (1.01) Helen talks about variation in prescription of opioids - do 1% of clinician really prescribe the vast majority of the drug? (8.45) Carl tells us that its time papers (in this case a lung screening one) really present absolute numbers. (17.30) Carl explains how a spoonfull (less) of salt helps the blood pressure go down (21.25) Helen puts test results under a microscope, and finds out that they may vary. (33.20) What do conflicts of interest in tanning papers mean for wider science? (48.05) Carl has a "super-rant" about smartphone apps for skin cancer - and a sensitivity of 0. Reading list: Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study https://www.bmj.com/content/368/bmj.l6968 Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1911793 Effect of dose and duration of reduction in dietary sodium on blood pressure levels https://www.bmj.com/content/368/bmj.m315 Your results may vary: the imprecision of medical measurements https://www.bmj.com/content/368/bmj.m149 Association between financial links to indoor tanning industry and conclusions of published studies on indoor tanning: systematic review https://www.bmj.com/content/368/bmj.m7 Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies https://www.bmj.com/content/368/bmj.m127

This edition of talk evidence was recorded before the big increase in covid-19 infections in the UK, and then delayed by some self isolation. We'll be back with more evidence on the pandemic very soon. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence). in this episode (1.01) Helen talks about variation in prescription of opioids - do 1% of clinician really prescribe the vast majority of the drug? (8.45) Carl tells us that its time papers (in this case a lung screening one) really present absolute numbers. (17.30) Carl explains how a spoonfull (less) of salt helps the blood pressure go down (21.25) Helen puts test results under a microscope, and finds out that they may vary. (33.20) What do conflicts of interest in tanning papers mean for wider science? (48.05) Carl has a "super-rant" about smartphone apps for skin cancer - and a sensitivity of 0. Reading list: Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study https://www.bmj.com/content/368/bmj.l6968 Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1911793 Effect of dose and duration of reduction in dietary sodium on blood pressure levels https://www.bmj.com/content/368/bmj.m315 Your results may vary: the imprecision of medical measurements https://www.bmj.com/content/368/bmj.m149 Association between financial links to indoor tanning industry and conclusions of published studies on indoor tanning: systematic review https://www.bmj.com/content/368/bmj.m7 Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies https://www.bmj.com/content/368/bmj.m127

Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence)* This month: (1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice. (4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients. (11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc. (17.46) Helen drops and EBM bombshell - is all the work needed to blind participants in a double blind randomised control trial actually worth it? (33.00) Helen is annoyed about a press release from the department of health, and kicks of 2020 by stealing Carl's rant spot. Reading list: Corticosteroids for Treating Sepsis in Children and Adults https://pubmed.ncbi.nlm.nih.gov/31808551-corticosteroids-for-treating-sepsis-in-children-and-adults/?dopt=Abstract Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline https://www.bmj.com/content/368/bmj.l6722 Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. https://www.ncbi.nlm.nih.gov/pubmed/31910280 Blinding Fool's gold? Why blinded trials are not always best https://www.bmj.com/content/368/bmj.l6228 Impact of blinding on estimated treatment effects in randomised clinical trials https://www.bmj.com/content/368/bmj.l6802 *quick note to say sorry about the sound quality on Duncan's microphone - we had a technical glitch (he was left alone to record).

Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence)* This month: (1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice. (4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients. (11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc. (17.46) Helen drops and EBM bombshell - is all the work needed to blind participants in a double blind randomised control trial actually worth it? (33.00) Helen is annoyed about a press release from the department of health, and kicks of 2020 by stealing Carl's rant spot. Reading list: Corticosteroids for Treating Sepsis in Children and Adults https://pubmed.ncbi.nlm.nih.gov/31808551-corticosteroids-for-treating-sepsis-in-children-and-adults/?dopt=Abstract Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline https://www.bmj.com/content/368/bmj.l6722 Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. https://www.ncbi.nlm.nih.gov/pubmed/31910280 Blinding Fool's gold? Why blinded trials are not always best https://www.bmj.com/content/368/bmj.l6228 Impact of blinding on estimated treatment effects in randomised clinical trials https://www.bmj.com/content/368/bmj.l6802 *quick note to say sorry about the sound quality on Duncan's microphone - we had a technical glitch (he was left alone to record).

Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence) This month: (2.00) Helen look back at a Christmas article, which investigates a very common superstition in hospitals. (7.55) Carl has his pick of the top 100 altimetric most influential papers of the year. (12.40) We find out all about the preventing overdiagnosis conference which happened earlier in December. (34.15) Helen has her annual rant about misogeny in medicine. Reading list: Q fever—the superstition of avoiding the word “quiet” as a coping mechanism https://www.bmj.com/content/367/bmj.l6446 Altimetric Top 100 https://www.altmetric.com/top100/2019/ Fiona Godlee's keynote at Preventing Overdiagnosis https://www.preventingoverdiagnosis.net/ Gender differences in how scientists present the importance of their research: observational study https://www.bmj.com/content/367/bmj.l6573

Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University's CEBM and editor of BMJ Evidence) This month: (2.00) Helen look back at a Christmas article, which investigates a very common superstition in hospitals. (7.55) Carl has his pick of the top 100 altimetric most influential papers of the year. (12.40) We find out all about the preventing overdiagnosis conference which happened earlier in December. (34.15) Helen has her annual rant about misogeny in medicine. Reading list: Q fever—the superstition of avoiding the word “quiet” as a coping mechanism https://www.bmj.com/content/367/bmj.l6446 Altimetric Top 100 https://www.altmetric.com/top100/2019/ Fiona Godlee's keynote at Preventing Overdiagnosis https://www.preventingoverdiagnosis.net/ Gender differences in how scientists present the importance of their research: observational study https://www.bmj.com/content/367/bmj.l6573

Nelson y Matías explican las historia y evolución de las diferentes escalas para la jerarquía de la evidencia clínica, y cómo éstas dan origen a los grados de recomendación. Algunos artículos recomendados: Los Niveles de evidencia y su evolución (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124652/) , el modelo de práctica basada en evidencia del Johanna Briggs Institute (https://joannabriggs.org/jbi-approach.html) , los niveles de evidencia según el CEBM de Oxford (https://www.cebm.net/category/ebm-resources/loe/) , y el grupo GRADE de trabajo sobre evidencia y recomendación en clínica (http://www.gradeworkinggroup.org) .

Professor Carl Heneghan has extensive experience of working with the media. In this talk he will discuss some recent case examples, working with the BBC amongst others. This talk will discuss how using an evidence-based approach can help overcome the growing problem of fake news, and provide insights on how to work with the media to ensure your message is not distorted, and will discuss why academics should engage more with the media and the wider public. Professor Carl Heneghan is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice.

Professor Carl Heneghan has extensive experience of working with the media. In this talk he will discuss some recent case examples, working with the BBC amongst others. This talk will discuss how using an evidence-based approach can help overcome the growing problem of fake news, and provide insights on how to work with the media to ensure your message is not distorted, and will discuss why academics should engage more with the media and the wider public. Professor Carl Heneghan is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice.

Professor Carl Heneghan gives a talk for the Evidence Based Healthcare series. Patients are being let down by serious flaws in the creation, dissemination, and implementation of medical research. Too much of the resulting research evidence is withheld or disseminated only piecemeal. As the volume of clinical research activity has grown, the quality of evidence has often worsened, which has compromised medicine's ability to provide affordable, effective, high-value care for patients. Professor Carl Heneghan will discuss the CEBM initiatives that have grown out of EBM Live, a yearly conference designed to "develop, disseminate, and implement better evidence for better healthcare. He is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice. In preparation for this talk you are invited to read the following: https://doi.org/10.1136/bmj.j2973

Professor Carl Heneghan gives a talk for the Evidence Based Healthcare series. Patients are being let down by serious flaws in the creation, dissemination, and implementation of medical research. Too much of the resulting research evidence is withheld or disseminated only piecemeal. As the volume of clinical research activity has grown, the quality of evidence has often worsened, which has compromised medicine's ability to provide affordable, effective, high-value care for patients. Professor Carl Heneghan will discuss the CEBM initiatives that have grown out of EBM Live, a yearly conference designed to "develop, disseminate, and implement better evidence for better healthcare. He is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice. In preparation for this talk you are invited to read the following: https://doi.org/10.1136/bmj.j2973

Professor Carl Heneghan and Dr David Nunan from the Oxford Centre for Evidence-Based Medicine presented the launch of a new website that catalogues the important biases affecting health and medical research. The website is in response to a call-to-arms raised nearly 40 years ago by the late David Sackett, where he called for 'The continued development of an annotated catalog of bias. Each citation should include a useful definition, a referenced example illustrating the magnitude and direction of its effects, and a description of the appropriate preventive measures, if any. I volunteer for this task, would welcome collaboration, and would appreciate receiving nominations and examples of additional biases.' In honour of David's memory and legacy, the CEBM have taken up where he left off. We are now ready to share the catalogue with the rest of the world for welcome feedback, discussion and further evolution. Additional input from Professor Sir Iain Chalmers. This talk was held as part of the Practice of Evidence-Based Health Care course which is part of the Evidence-Based Health Care Programme.

Professor Carl Heneghan and Dr David Nunan from the Oxford Centre for Evidence-Based Medicine presented the launch of a new website that catalogues the important biases affecting health and medical research. The website is in response to a call-to-arms raised nearly 40 years ago by the late David Sackett, where he called for 'The continued development of an annotated catalog of bias. Each citation should include a useful definition, a referenced example illustrating the magnitude and direction of its effects, and a description of the appropriate preventive measures, if any. I volunteer for this task, would welcome collaboration, and would appreciate receiving nominations and examples of additional biases.' In honour of David's memory and legacy, the CEBM have taken up where he left off. We are now ready to share the catalogue with the rest of the world for welcome feedback, discussion and further evolution. Additional input from Professor Sir Iain Chalmers. This talk was held as part of the Practice of Evidence-Based Health Care course which is part of the Evidence-Based Health Care Programme.

The overwhelming volume of evidence and its lack of relevance to patient care and decisions means health professionals require skills to sift evidence more efficiently: discarding what doesn't make a difference to focus on evidence that matters for health This talk will present a simple effective appraisal system based on two first steps to rapidly appraise and sift the evidence for its relevance and application to actual patient care, prior to assessing its validity. Professor Carl Heneghan is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice. This talk is being held as part of the Practice of Evidence-Based Health Care module which is part of the MSc in Evidence-Based Health Care and the MSc in EBHC Systematic Reviews.

The overwhelming volume of evidence and its lack of relevance to patient care and decisions means health professionals require skills to sift evidence more efficiently: discarding what doesn't make a difference to focus on evidence that matters for health This talk will present a simple effective appraisal system based on two first steps to rapidly appraise and sift the evidence for its relevance and application to actual patient care, prior to assessing its validity. Professor Carl Heneghan is Director of CEBM, and an NHS Urgent Care GP, and has been interested for over twenty years in how we can use evidence in real world practice. This talk is being held as part of the Practice of Evidence-Based Health Care module which is part of the MSc in Evidence-Based Health Care and the MSc in EBHC Systematic Reviews.

Professor Carl Heneghan gives a talk for the Centre for Evidence Based Medicine podcast series. EBM has been transformational for healthcare, however, currently it is poorly understood how this has occurred over time. Using Heart Attack as an example, Prof Carl Heneghan will demonstrate and discuss how EBM has saved lives, and invite the audience to consider the consequence of a health system without evidence. More informatiopn can be found here; www.cebm.net/what-has-ebm-done-for-healthcare/

Professor Carl Heneghan gives a talk for the Centre for Evidence Based Medicine podcast series. EBM has been transformational for healthcare, however, currently it is poorly understood how this has occurred over time. Using Heart Attack as an example, Prof Carl Heneghan will demonstrate and discuss how EBM has saved lives, and invite the audience to consider the consequence of a health system without evidence. More informatiopn can be found here; www.cebm.net/what-has-ebm-done-for-healthcare/

This talk will introduce the realist review methodology as a strategy for combining qualitative and quantitative data to answer the question “what works, for whom, and in what circumstances” This methodology is proving popular in addressing questions around complex and social interventions. The talk will provide a brief overview of approaches to synthesizing qualitative and quantitative research for mixed methods reviews, discuss approaches to dealing with different study types in realist reviews, and question the adequacy of published studies when developing theory for complex interventions.

The need to generate systematic reviews is relatively uncontroversial and until recently so were the methods of production. The presentation will highlight a number of problems associated with the current system and propose a radical departure to ensure we meet Archie Cochrane's desire to see all RCTs included in critical summaries.

This talk will introduce the realist review methodology as a strategy for combining qualitative and quantitative data to answer the question “what works, for whom, and in what circumstances” This methodology is proving popular in addressing questions around complex and social interventions. The talk will provide a brief overview of approaches to synthesizing qualitative and quantitative research for mixed methods reviews, discuss approaches to dealing with different study types in realist reviews, and question the adequacy of published studies when developing theory for complex interventions.

The need to generate systematic reviews is relatively uncontroversial and until recently so were the methods of production. The presentation will highlight a number of problems associated with the current system and propose a radical departure to ensure we meet Archie Cochrane's desire to see all RCTs included in critical summaries.

Carl Heneghan is a Professor of Evidence-Based Medicine and a Primary Care Physician and has over 20 years experience of using evidence in practice for changing health care. This talk will give you an understanding of how you might get involved in the modern era of EBM improvement and what you could do to support the application of evidence into practice.

Carl Heneghan is a Professor of Evidence-Based Medicine and a Primary Care Physician and has over 20 years experience of using evidence in practice for changing health care. This talk will give you an understanding of how you might get involved in the modern era of EBM improvement and what you could do to support the application of evidence into practice.

Today's youth face different challenges than those who came before them. CEBM founder Jean Rhodes looks at five skills that will help with the transition to adulthood.

What role does empathy play in mentoring relationships? CEBM editorial board member Renee Spencer delineates the role empathy plays in clinical relationships, and what this implies within the mentor/mentee dynamic.

CEBM director Jean Rhodes explains the importance of Best Practices and maintaining an evidence basis when working in the youth mentoring field.

Dr Carl Heneghan delivers a talk for the Centre for Evidence Based Medicine.

Professor Paul Glasziou, Director of the Centre for Evidence Based Medicine, gives a special lecture on the future of EBM.

Dr Amanda Burls delivers a talk for the Centre for Evidenced Based Medicine.

Dr Rafael Perera delivers a talk for the Centre for Evidence Based Medicine.

Sir Muir Gray, Chief Knowledge Office, NHS, gives a special guest lecture for the Centre for Evidence Based Medicine.

Professor Paul Glasziou gives an introduction to evidence-based medicine and healthcare.

Dr Carl Heneghan delivers a talk for the Centre for Evidence Based Medicine.

Dr Janet Martin, Director of Health Technology Assessment, London Health Services Centre gives a special lecture for EBM entitled; Know4Go: An Instrument for decision-making when resources are limited and demands are relentless.